Esketamine nasal spray
Treatment of resistant depression (NICE TA854)
1.1 Esketamine nasal spray with a selective serotonin reuptake inhibitor (SSRI) or a serotonin-norepinephrine reuptake inhibitor (SNRI) is not recommended, within its marketing authorisation, for treatment-resistant depression that has not responded to at least 2 different antidepressants in the current moderate to severe depressive episode in adults.
Reason for decision:
Not recommended for prescribing on the NHS in Lancashire & South Cumbria